February 16, 2018
A New Jersey federal judge on Thursday tossed a proposed class action alleging that Insmed Inc. misled investors over the likelihood that a lung disease drug would gain market approval in Europe, ruling that the biopharmaceutical company's alleged misstatements and omissions didn't meet the standards for securities law claims.
October 26, 2016
A New Jersey federal judge on Tuesday appointed Robbins Geller Rudman & Dowd LLP as lead counsel in a proposed class action alleging that biopharmaceutical company Insmed Inc. misled investors over the likelihood that a lung disease drug would gain market approval in Europe and its stock price dropped.